EclampsiaMANAGEMENT

OBSTETRIC PRESENTATIONS · 12 SECTIONS

⚲

581 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Chorioamnionitis Eclampsia Ectopic Pregnancy (Ruptured)Ectopic Pregnancy (Unruptured)HELLP Syndrome Hyperemesis gravidarum Peripartum cardiomyopathy Placenta previa Placental abruption Postpartum Endometritis Postpartum hemorrhage Postpartum infection Preeclampsia Preeclampsia-eclampsia Preterm labor Sepsis in pregnancy Septic abortion Shoulder dystocia Spontaneous Abortion (Incomplete)Spontaneous Abortion (Missed)Spontaneous Abortion (Threatened)Threatened-inevitable-incomplete abortion Umbilical cord prolapse

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp49

Immediate priorities

›Airway and breathing

›Left lateral decubitus positioning to prevent aspiration and optimize uteroplacental perfusion

›Do not restrain during active seizure

›Pad side rails

›Supplemental oxygen via face mask

›Target SpO2 >95%

›Suction at bedside

›If airway compromise or SpO2 unresponsive to oxygen, rapid sequence intubation

›Ketamine preferred induction agent in eclampsia

›Avoid succinylcholine if hyperkalemia suspected

›Seizure termination

›Magnesium sulfate 4–6 g IV over 15–20 minutes

›First-line agent superior to phenytoin, diazepam, and lytic cocktail

›If already on prophylactic magnesium, give additional 2–4 g IV bolus

›Benzodiazepine only if magnesium contraindicated or unavailable

›Diazepam 5–10 mg IV or lorazepam 2–4 mg IV

›Caution: aspiration and respiratory depression risk

›Hemodynamic stabilization

›Severe hypertension target: reduce to <160/110 mmHg within 30–60 minutes

›IV labetalol: 20 mg then 40 mg then 80 mg every 10–20 minutes (max 300 mg)

›IV hydralazine: 5–10 mg every 20 minutes

›Oral nifedipine IR: 10–20 mg every 20–30 minutes if no IV access

›Avoid precipitous BP drop (risk of placental hypoperfusion)

›MAP reduction target <25% in first hour

Team activation and consults

›Immediate OB consultation

›Emergent delivery planning

02History/hx58

Seizure characterization

›Onset and timing

›Gestational age at onset

›Antepartum (50%), intrapartum, or postpartum (50% — most within 48 hours, up to 6 weeks)

›Duration of seizure and number of episodes

›Seizure type

›Tonic-clonic most common

›Focal or multifocal pattern

›Postictal state duration

›Preceding prodromal symptoms (present in ~80%)

›Severe persistent headache (frontal or occipital)

›Visual disturbances: scotomata, blurred vision, photophobia, flashing lights

›Altered cognition or confusion

Associated symptoms

›Neurologic

›Headache character and severity

›Visual changes

›Focal weakness or sensory loss

›Tongue biting or incontinence during event

›Gastrointestinal and hepatic

›Epigastric or RUQ pain (hepatic involvement, HELLP)

›Nausea and vomiting

›Malaise

›Renal

›Decreased urine output

›Dark urine

›Facial or hand edema (more concerning than dependent edema)

›Pulmonary and cardiovascular

03Physical Exam/exam42

Vital signs

›Blood pressure

›Severe range >=160/110 mmHg in one or both arms

›BP can be normal in up to 20–38% of eclampsia cases

›Repeat measurements 4 minutes apart to confirm severe range

›Heart rate and rhythm

›Tachycardia from seizure, pain, or hypovolemia

›Respiratory rate and oxygen saturation

›Hypoxia from aspiration or pulmonary edema

›Respiratory depression on magnesium infusion

Neurologic exam

›Mental status

›Postictal confusion or agitation

›Depth of altered consciousness

›GCS score

›Deep tendon reflexes

›Hyperreflexia (3+ to 4+) suggests ongoing central nervous system irritability

›Clonus: >=3 beats significant for preeclampsia with severe features

›Loss of reflexes indicates magnesium toxicity

›Focal neurologic findings

›Visual field deficits

›Focal weakness or asymmetry

›Cranial nerve abnormalities

Eyes

›Fundoscopic examination

›Papilledema (raised intracranial pressure)

›Retinal vasospasm or hemorrhage

›Pupillary reactivity

04Differential Diagnosis/ddx49

Neurologic causes

›Epilepsy

›ICD-10: G40.909

›Prior seizure history, normal BP, no proteinuria, no obstetric context

›Antiepileptic medication use

›Intracranial hemorrhage

›ICD-10: I62.9

›Subarachnoid or intracerebral hemorrhage

›Sudden severe thunderclap headache, focal deficits, CT head to differentiate

›Cerebral venous sinus thrombosis

›ICD-10: I67.6

›Headache, seizures, focal deficits; pregnancy is a risk factor

›MRI/MRV for diagnosis

›Posterior reversible encephalopathy syndrome (PRES)

›ICD-10: G93.49

›Significant overlap with eclampsia; MRI shows vasogenic edema in posterior brain

›May coexist with eclampsia

›Reversible cerebral vasoconstriction syndrome (RCVS)

›ICD-10: G43.909

›Thunderclap headache, may mimic eclampsia

›CT angiography or MRA for diagnosis

›Ischemic stroke

›ICD-10: I63.9

›Focal deficits, CT/MRI for differentiation

Infectious causes

›Bacterial meningitis

›ICD-10: G00.9

›Fever, meningismus, photophobia, Kernig and Brudzinski signs

05Laboratory Tests/lt37

Complete blood count

›CBC with platelets

›Platelets <100,000/microL diagnostic of HELLP syndrome

›Platelets <150,000/microL with preeclampsia indicate severe features

›Hemoglobin trend for hemolysis or hemorrhage

Metabolic and renal panel

›Basic metabolic panel

›Creatinine >=88 micromol/l (1 mg/dL) or >2x baseline indicates severe renal involvement

›Glucose to exclude hypoglycemia as seizure trigger

›Electrolytes including sodium, potassium, magnesium

›Uric acid

›Elevated in preeclampsia/eclampsia; severity marker

›Not diagnostic but supports assessment

Hepatic markers

›Liver function tests

›AST and ALT >2x upper limit of normal indicates HELLP hepatic involvement

›Total bilirubin elevation in hemolysis

›Lactate dehydrogenase

›LDH >=600 U/L in HELLP syndrome (hemolysis marker)

Coagulation and hematology

›Coagulation panel

›PT/INR and aPTT for DIC screening

›Fibrinogen: low fibrinogen (<200 mg/dL equivalent) indicates consumptive coagulopathy

›Peripheral blood smear

›Schistocytes confirm microangiopathic hemolytic anemia

Urinalysis and proteinuria

›Urinalysis with microscopy

›Dipstick proteinuria >=2+ warrants quantification

06Diagnostic Tests/dt61

Scoring Systems

›Fullerton diagnostic criteria for eclampsia

›New-onset tonic-clonic or focal seizures in pregnant or postpartum patient

›After exclusion of other neurologic etiologies

›Primarily a clinical diagnosis; no formal validated scoring system

›Preeclampsia with severe features (ACOG criteria)

›BP >=160/110 mmHg on two occasions 4 minutes apart

›Platelet count <100,000/microL

›Serum creatinine >88 micromol/l in absence of renal disease

›Liver enzymes >2x normal with RUQ pain

›Pulmonary edema

›New-onset headache unresponsive to medication

›HELLP diagnostic criteria (Tennessee classification)

›Hemolysis: LDH >=600 U/L, schistocytes, bilirubin >20 micromol/l

›Elevated liver enzymes: AST >=70 U/L

›Low platelets: <100,000/microL

›Magee modified PIERS model

›Predicts adverse maternal outcomes in preeclampsia

›Incorporates gestational age, symptoms, SpO2, platelets, creatinine, liver enzymes

MRI

›Brain MRI without contrast

›Gold standard for diagnosing posterior reversible encephalopathy syndrome (PRES)

›T2/FLAIR hyperintensities in posterior parieto-occipital regions

›Vasogenic edema pattern distinguishes PRES from ischemic stroke

›MRI indications in eclampsia

›Atypical seizure presentation or refractory seizures on magnesium

›Focal neurologic deficits persisting after seizure termination

›Seizure onset >48–72 hours postpartum

07Disposition/dispo33

Admission criteria

›ICU or high-acuity admission

›All eclampsia cases require ICU-level or labor and delivery with 1:1 nursing monitoring

›No outpatient management under any circumstances

›Magnesium sulfate infusion requires continuous monitoring

›Labor and delivery unit criteria

›Hemodynamically stable with controlled BP

›No persistent altered mental status or focal deficits

›Fetal monitoring available

Transfer criteria

›Immediate transfer indications

›Delivering facility lacks obstetric surgery, anesthesia, NICU, or ICU capabilities

›Refractory seizures or hemodynamic instability after initial stabilization

›Transfer stabilization requirements

›Magnesium sulfate infusion running during transport

›Antihypertensive therapy titrated before departure

›IV access and airway equipment available

›Fetal monitoring during transport if feasible

Specialist consultations

›Required consultations

›Obstetrics: emergent for delivery planning

›Anesthesia: for delivery analgesia and airway management

›Neonatology: if <35 weeks or fetal compromise

›Conditional consultations

›Neurology: atypical features, refractory seizures, or suspected alternative neurologic diagnosis

›Maternal-fetal medicine: complex cases, severe early-onset disease <34 weeks

›Nephrology: renal failure or dialysis consideration

08Treatment/t75

Magnesium sulfate

›Loading dose

›4–6 g IV over 15–20 minutes

›Dilute in 100 mL normal saline or D5W

›Administer via controlled infusion pump

›If already on prophylactic magnesium: 2–4 g IV additional bolus

›Maintenance infusion

›1–2 g/hour continuous IV infusion

›Continue for 24–48 hours postpartum or 24 hours after last seizure

›Dose reduce in renal impairment (CrCl <25 mL/min: reduce to 0.5–1 g/hour with serum levels)

›Toxicity monitoring

›Respiratory rate >12/min

›Deep tendon reflexes present

›Urine output >25–30 mL/hour

›Serum magnesium level if toxicity suspected

›Antidote

›Calcium gluconate 1 g IV over 3 minutes for respiratory depression or cardiac toxicity

›Evidence level

›Superior to phenytoin, diazepam, and lytic cocktail for seizure prevention and treatment

›Class I recommendation; Cochrane meta-analysis supports MgSO4 as first-line

›IM alternative (resource-limited settings)

›5 g into each buttock (10 g total IM loading) then 5 g IM every 4 hours

›Dilute in 1 mL of 2% lidocaine to reduce injection pain

Antihypertensive therapy

›Treatment threshold

›Initiate for BP >=160/110 mmHg confirmed on two readings 4 minutes apart

›Target: reduce to <160/110 mmHg without precipitous drop

›MAP reduction no more than 25% in first hour

›ACOG Level A recommendation for treatment within 30–60 minutes

›IV labetalol

›20 mg IV bolus then 40 mg then 80 mg every 10–20 minutes

›Maximum cumulative dose: 300 mg

›Contraindicated in asthma, severe bradycardia, decompensated heart failure

›IV hydralazine

›5–10 mg IV every 20 minutes

›Maximum cumulative dose: 30 mg per episode

›Risk of reflex tachycardia and maternal hypotension

›Oral nifedipine immediate-release

›10–20 mg orally every 20–30 minutes if IV access unavailable

›Maximum dose: 60 mg in 24 hours as acute agent

›Caution when combined with magnesium sulfate (risk of enhanced hypotension)

›Contraindicated antihypertensives

›ACE inhibitors (teratogenic)

›Angiotensin receptor blockers (teratogenic)

›Direct renin inhibitors (teratogenic)

›Atenolol (fetal growth restriction)

Delivery planning

›Delivery as definitive treatment

›Only cure for eclampsia

›Timing and mode determined by gestational age and maternal/fetal status

›Stabilize mother before rushing to cesarean

›Most seizures are self-limited (60–90 seconds); do not perform emergency cesarean during active seizure

›Fetal heart tracing typically normalizes with maternal resuscitation

›Mode of delivery

›Vaginal delivery preferred if not contraindicated and cervical status favorable

›Epidural analgesia preferred for pain control and BP management

›Oxytocin augmentation acceptable

›Cesarean delivery for standard obstetric indications or if vaginal delivery not feasible

›Corticosteroids for fetal lung maturity

›Betamethasone 12 mg IM x2 doses 24 hours apart if <34 weeks and delivery can be safely delayed 48 hours

›Do not delay delivery if maternal instability to give steroids

Seizure recurrence management

›Recurrent seizure on magnesium

›Additional 2 g magnesium IV bolus over 3–5 minutes

›Consider increasing maintenance rate to 2 g/hour if not already at maximum

›If persistent or refractory, consider alternative etiology

›CT or MRI head urgently

›Neurology consultation

›Refractory seizures (not responding to magnesium)

›Lorazepam 2–4 mg IV or diazepam 5–10 mg IV

›Intubation if unable to maintain airway

›Phenytoin or levetiracetam if structural epilepsy confirmed

›Levetiracetam 1500 mg IV over 15 minutes as adjunct

Fluid management

›Judicious IV fluid management

›Fluid restriction to avoid pulmonary edema (risk in preeclampsia/eclampsia)

›Limit to 80–125 mL/hour total IV fluids including drug infusions

›Furosemide 20–40 mg IV for pulmonary edema

›Avoid aggressive fluid boluses

›Oliguria in eclampsia often reflects vasoconstriction, not volume depletion

09Special Populations/sp42

Pregnancy

›Antepartum management (before delivery)

›Left lateral decubitus positioning throughout

›Reduces aortocaval compression

›Optimizes uteroplacental blood flow

›Continuous electronic fetal monitoring mandatory

›Expect prolonged decelerations during and after seizure

›Biophysical profile if monitoring non-reassuring after resuscitation

›Regional anesthesia (epidural) preferred over general anesthesia

›Lower laryngeal edema risk

›Superior BP control

›Medication safety in pregnancy

›Magnesium sulfate: safe and preferred; crosses placenta (neonatal hypermagnesemia possible)

›Neonatal calcium gluconate may be needed if prolonged maternal infusion

›Labetalol: Category C; preferred IV antihypertensive in pregnancy

›Hydralazine: Category C; well established in obstetric use

›Nifedipine: generally safe in pregnancy; watch for hypotension with magnesium

›Avoid ACE inhibitors, ARBs, atenolol, and direct renin inhibitors (teratogenic)

›Postpartum-onset eclampsia

›50% of eclampsia cases are intrapartum or postpartum

›Most within 48 hours of delivery

›Late postpartum eclampsia: 48 hours to 6 weeks after delivery

›Maintain high suspicion for seizures in postpartum patients with new headache or BP elevation

›Magnesium sulfate for 24–48 hours after last seizure

Geriatric

›Eclampsia does not occur in elderly patients

›Condition is specific to pregnancy and postpartum period up to 6 weeks

›If elderly patient with seizure and hypertension, consider PRES, hypertensive encephalopathy, or stroke

10Background/b60

Epidemiology

›Incidence and global burden

›Incidence 1.6–10 per 10,000 deliveries in developed countries

›Up to 151 per 10,000 in developing countries

›Leading cause of maternal mortality globally

›Temporal distribution

›50% antepartum

›50% intrapartum or postpartum (most within 48 hours)

›Demographics and disparities

›Nulliparity is strongest single obstetric risk factor

›Risk decreases in subsequent pregnancies unless chronic risk factors persist

›Black patients have disproportionately higher prevalence and complication rates

›Structural and systemic factors contribute to racial health disparities

›Preeclampsia affects 5–8% of pregnancies; eclampsia develops in 2–3% of severe preeclampsia cases

›Mortality

›Remains a leading cause of maternal morbidity and mortality in both developed and developing settings

›Complications include placental abruption, DIC, pulmonary edema, aspiration pneumonia, cardiopulmonary arrest, acute renal failure, and maternal death

›Long-term sequelae: increased cardiovascular risk, recurrence risk, cognitive effects

Pathophysiology

›Central nervous system mechanism

›Cerebral vasospasm and loss of autoregulation leading to vasogenic edema

›Manifests as posterior reversible encephalopathy syndrome (PRES) in most cases

›Posterior cerebral regions most vulnerable due to reduced sympathetic innervation

›Seizure threshold lowered by cerebral edema, ischemia, and microhemorrhages

›Not fully explained by hypertension alone

›20–38% have no prior documented hypertension or proteinuria

›Placental pathophysiology

›Abnormal placentation with inadequate spiral artery remodeling

›Placental ischemia leads to release of anti-angiogenic factors (sFlt-1) and reduced PlGF

›Endothelial dysfunction, vasoconstriction, and organ injury result

›Two-stage model

›Stage 1: abnormal placentation (subclinical)

›Stage 2: maternal systemic inflammatory response and endothelial activation

›End-organ effects

›Renal: glomerular endotheliosis, proteinuria, AKI

›Hepatic: periportal hemorrhage, necrosis (HELLP)

›Hematologic: microangiopathic hemolytic anemia, thrombocytopenia, DIC

›Cardiac: increased afterload, diastolic dysfunction, pulmonary edema

Therapeutic Considerations

›Why magnesium works

›Mechanism not fully elucidated; proposed mechanisms include:

›Cerebral vasodilation reducing ischemic threshold

›N-methyl-D-aspartate (NMDA) receptor antagonism reducing neuronal excitability

›Membrane stabilization

›Superiority established over phenytoin, diazepam, and lytic cocktail in Magpie Trial and Collaborative Eclampsia Trial

›Antihypertensive selection rationale

›Labetalol preferred: combined alpha and beta blockade; rapid, titratable effect

›Avoids reflex tachycardia seen with hydralazine

›Hydralazine: direct arteriolar vasodilator; well-established in obstetric use

›Less predictable response; risk of maternal hypotension

›Nifedipine IR: rapid oral onset; convenient when IV access unavailable

›Evidence does not support avoidance with magnesium, but close BP monitoring required

›Delivery timing evidence

›Delivery at >=37 weeks recommended for all preeclampsia

›At >=34 weeks for severe features (including eclampsia): deliver after stabilization

›Expectant management <34 weeks only in selected patients at tertiary center with maternal stabilization

›Magnesium prophylaxis post-delivery reduces recurrent eclampsia risk

›Long-term cardiovascular risk

›Eclampsia associated with significantly increased lifetime risk of:

›Hypertension, ischemic heart disease, stroke

›Risk persists decades after pregnancy

›Cognitive effects: memory and concentration difficulties reported

›Permanent white matter loss on MRI in up to 25% of patients

11Patient Discharge Instructions/pdi35

copy discharge instructions

›When to return to the emergency department immediately

›New or recurrent seizure at any time

›Call 911; do not drive

›Severe headache that is sudden, the worst of your life, or unresponsive to acetaminophen

›Visual changes: blurring, flashing lights, seeing spots, or loss of vision

›Epigastric or right upper abdominal pain

›Shortness of breath or chest pain

›Decreased urine output or absent urine output

›Swelling of your face or hands that is rapidly worsening

›Decreased fetal movement (if still pregnant)

›Vaginal bleeding

›Blood pressure monitoring instructions

›Home BP monitoring required after discharge

›Check BP at least twice daily

›Record readings in a log or app

›Return immediately if BP >=160/110 mmHg

›BP peaks 3–6 days after delivery

›This is the highest-risk window for new postpartum seizures

›Medications

›Take all prescribed blood pressure medications exactly as directed

›Do not stop medications without physician guidance even if you feel well

›Most antihypertensives prescribed are compatible with breastfeeding

›Avoid NSAIDs (ibuprofen, naproxen) if kidney function is reduced or BP is elevated

›No ACE inhibitors or ARBs if planning future pregnancy

›Follow-up appointments

›OB or midwife visit within 3–7 days for BP check and lab review

›Comprehensive postpartum visit at 6 weeks

12References/r40

Guidelines and key sources

›Boushra M, Natesan SM, Koyfman A, Long B.

›High Risk and Low Prevalence Diseases: Eclampsia

›American Journal of Emergency Medicine. 2022

›PMID: 35716535

›Fishel Bartal M, Sibai BM.

›Eclampsia in the 21st Century

›American Journal of Obstetrics and Gynecology. 2022

›PMID: 32980358

›Committee on Practice Bulletins — Obstetrics.

›Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Number 222

›Obstetrics and Gynecology. 2020

›DOI: 10.1097/AOG.0000000000003891

›Chappell LC, Cluver CA, Kingdom J, Tong S.

›Pre-Eclampsia

›Lancet. 2021

›PMID: 34051884

›Magee LA, Nicolaides KH, von Dadelszen P.

›Preeclampsia

›New England Journal of Medicine. 2022

›DOI: 10.1056/NEJMra2109523

›Farahi N, Oluyadi F, Dotson AB.

›Hypertensive Disorders of Pregnancy

›American Family Physician. 2024

›PMID: 38574215

›Diaz V, Long Q, Oladapo OT.

›Alternative Magnesium Sulphate Regimens for Women With Pre-Eclampsia and Eclampsia

›Cochrane Database of Systematic Reviews. 2023

Learn More: Eclampsia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.